The more cortical amyloid‐β, the more postural instability in parkinson's disease: More grist to the mill for a link between walking, falling, and remembering?

Yaroslau Compta, MD, Tamas Revesz, MD, and Andrew J. Lees, MD, F MedSci* Parkinson’s Disease & Movement Disorders Unit, Neurology Service, Institut Clı́nic de Neurociències, IDIBAPS, CIBERNED, Hospital Clı́nic, Barcelona, Catalonia, Spain Queen Square Brain Bank for Neurological Disorders, Institute of Neurology, University College of London, London, UK Reta Lila Weston Institute, Institute of Neurology, University College of London, London, UK

[1]  R. Albin,et al.  β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[2]  Turi O. Dalaker,et al.  Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[3]  Turi O. Dalaker,et al.  Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  R. Albin,et al.  Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia , 2012, Neurology.

[5]  Keith A. Johnson,et al.  Brain amyloid and cognition in Lewy body diseases , 2012, Movement disorders : official journal of the Movement Disorder Society.

[6]  Constantinos Kallis,et al.  Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? , 2011, Brain : a journal of neurology.

[7]  Nicolaas I. Bohnen,et al.  White matter lesions in Parkinson disease , 2011, Nature Reviews Neurology.

[8]  S. Gentleman,et al.  Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes , 2011, Neurobiology of Disease.

[9]  J. Jankovic,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Trojanowski,et al.  CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.

[11]  K. Blennow,et al.  CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  J. Trojanowski,et al.  Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline , 2010, The Journal of Neuroscience.

[13]  E. Tolosa,et al.  Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[14]  T Revesz,et al.  A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.

[15]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  K. Jellinger.  Striatal beta-amyloid deposition in Parkinson disease with dementia. , 2008, Journal of neuropathology and experimental neurology.

[17]  M. Graeber,et al.  Striatal &bgr;-Amyloid Deposition in Parkinson Disease With Dementia , 2008, Journal of neuropathology and experimental neurology.

[18]  G. Halliday,et al.  The progression of pathology in longitudinally followed patients with Parkinson’s disease , 2008, Acta Neuropathologica.

[19]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[20]  T. Robbins,et al.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. , 2007, Brain : a journal of neurology.

[21]  E. Perry,et al.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.

[22]  D. Aarsland,et al.  Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[23]  D. Aarsland,et al.  Cognitive Predictors of Dementia in Parkinson’s Disease: A Community-Based, 4-Year Longitudinal Study , 2005, Journal of geriatric psychiatry and neurology.

[24]  J. Troncoso,et al.  Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases , 2005, Neurobiology of Aging.

[25]  J. Troncoso,et al.  Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. , 2005, Neurobiology of aging.

[26]  D. Aarsland,et al.  Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. , 2003, Archives of neurology.

[27]  Joseph E Parisi,et al.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.

[28]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.